Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyCareSource Experimental Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Experimental and Investigational Item or Service

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs CareSource coverage determinations for health care items and services considered experimental or investigational, including medical, surgical, diagnostic, behavioral health, substance use disorder, drug, biologic, device, and technology-related services. Experimental or investigational items and services are generally not covered, while requests for members under age 21 are individually reviewed for medical necessity.

    Policy Summary
    PayerCareSource
    PolicyExperimental and Investigational Item or Service
    Policy CodePolicy N/A
    Change TypeMaterial revision: EPSDT individual review added
    Effective DateDecember 25, 2030
    Last ReviewAug 12, 2026
    Next Review DateN/A
    Key ActionProvide available clinical, regulatory, medical, and research records to support coverage review.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added an EPSDT requirement stating that requests for members under age 21 are individually reviewed to determine medical necessity.

    The policy added research records to the list of evidence CareSource may consider during review.

    The policy history records updates to references and committee approval.

    Not coveredDefault coverage status for experimental or investigational items and services
    Under 21Requests reviewed individually for medical necessity under EPSDT
    6
    Policy Summary
    PayerCareSource
    PolicyExperimental and Investigational Item or Service
    Policy CodePolicy N/A
    Change TypeMaterial revision: EPSDT individual review added
    Effective DateDecember 25, 2030
    Last ReviewAug 12, 2026
    Next Review DateN/A
    Key ActionProvide available clinical, regulatory, medical, and research records to support coverage review.
    SourceLink
    On This Page
    Experimental or Investigational Coverage CriteriaReview Considerations and Denial RisksPolicy Scope and ContextKey Definitions and Exceptions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Express definition-based circumstances that may make an item or service experimental or investigational
    8Evidence sources listed for experimental or investigational review
    Phase 4Drug trial phase that may be covered when the drug is on the formulary

    Experimental or Investigational Coverage Criteria

    Definition-Based Experimental or Investigational Status

    At the time CareSource makes a coverage determination, a health care item or service is experimental or investigational if <strong>ANY</strong> of the following applies:

    ANY of the following

    • The item or service is not approved by the United States Food and Drug Administration (FDA) to be lawfully marketed for the proposed use.
    • The item or service is not identified in the American Hospital Formulary Service or the United States Pharmacopoeia Dispensing Information as appropriate for the proposed use, or the FDA has determined it is contraindicated for the specific use.
    • The item or service is subject to review and approval by an institutional review board or similar body for the proposed use, and final approval has not been granted.
    • The item or service is the subject of an ongoing Phase 1, 2, or 3 clinical trial as defined by FDA regulations, regardless of whether the trial is subject to FDA oversight, including screening or diagnostic testing for possible inclusion in a clinical trial.
    • The item or service is provided as part of a clinical research protocol or clinical trial, or in any other manner intended to evaluate the safety, toxicity, or efficacy of the drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply.
    • The item or service is provided pursuant to informed consent that describes it as experimental or investigational or otherwise indicates that its safety, toxicity, or efficacy is under evaluation.
    • The item or service is an FDA-approved Humanitarian Use Device.

      Humanitarian Use Devices approved under the FDA exemption are not considered experimental or investigational; this criterion does not apply.

    • A drug is used in a Phase 4 trial and is not part of the formulary.

      Drugs used in Phase 4 trials may be covered if they are part of the formulary; this criterion does not apply to formulary drugs.

    Evidence-Based Experimental or Investigational Status

    A health care item or service that does not meet the definition-based criteria above may still be determined to be experimental or investigational when it is not supported by credible research that soundly demonstrates a measurable and beneficial health outcome. CareSource considers information and evidence from one or more sources, including published authoritative, peer-reviewed medical or scientific literature or the absence thereof, and evaluations by national medical associations, consensus panels, and other technology evaluation bodies.

    ANY of the following evidence deficiencies

    • The scientific evidence is not conclusive concerning the effect of the health care item or service on health outcomes.
    • The evidence does not demonstrate that the health care item or service improves net health outcomes for the total population for whom it might be proposed by producing beneficial effects that outweigh harmful effects.
    • The evidence does not demonstrate that the health care item or service is as beneficial for the total population for whom it might be proposed as established alternatives.
    • The evidence does not demonstrate that the health care item or service improves net health outcomes for the total population for whom it might be proposed under the usual conditions of medical practice outside clinical investigatory settings.

    Members Under Age 21

    EPSDT does not require coverage of treatments, services, or items that are experimental or investigational. However, requested treatments for members under age 21 are reviewed individually to determine whether the request is medically necessary.

    The member is under age 21 and the requested treatment, service, or item requires an individual medical-necessity review.

    Any health care item or service CareSource determines to be experimental or investigational is not covered.

    Services or procedures determined not to be medically necessary are among the non-covered items or services. Experimental or investigational items or services may also include services or procedures considered cosmetic or not medically necessary.

    Review Considerations and Denial Risks

    Note

    Evidence Supporting Coverage Review

    CareSource reviews requested items and services using information and evidence from one or more sources to determine whether the service produces a measurable, beneficial health outcome and supports coverage.

    • Published authoritative, peer-reviewed medical or scientific literature, including the absence of such literature
    • Evaluations by national medical associations, consensus panels, and other technology-evaluation bodies
    • Documents issued by or filed with the FDA or another authorized federal, state, or local regulatory agency
    • Institutional review board or similar-body documents
    • Provider consent forms and written study protocols
    • Medical records and research records
    • Opinions of consulting providers and other subject-matter experts
    • The review also assesses whether evidence is conclusive about health outcomes; demonstrates benefits that outweigh harms for the total proposed population; shows the service is at least as beneficial as established alternatives; and demonstrates improved net health outcomes under usual, non-investigational conditions

    Policy Scope and Context

    Experimental or investigational items and services may involve a broad range of care, including medical, surgical, diagnostic, psychiatric, behavioral health, substance use disorder, drug, biologic, device, technology, equipment, and treatment-related services. CareSource generally excludes these services from coverage when they lack appropriate regulatory, clinical, or evidentiary support for the proposed use. Requests for members under age 21 are reviewed individually to determine medical necessity.

    Key Definitions and Exceptions

    CPT Category III Codes
    Code typeTemporary T codes
    Assigned toEmerging technologies, services, and procedures
    Primary purposeData collection to substantiate more widespread usage or documentation for the FDA approval process
    Experimental or Investigational Items or Services
    ScopeMedical, surgical, diagnostic, psychiatric, substance use disorder treatment, or other health care services, technologies, equipment, supplies, treatments, procedures, therapies, biologics, drugs, or devices
    FDA or recognized-use supportNot approved by the FDA for lawful marketing for the proposed use; not identified in the American Hospital Formulary Service or United States Pharmacopeia Dispensing Information as appropriate for the proposed use; or determined by the FDA to be contraindicated for the specific use
    Denial Risk

    Experimental or Investigational Status

    Any health care item or service CareSource determines to be experimental or investigational is not covered. Requests for members under age 21 are reviewed individually for medical necessity; EPSDT does not require coverage of experimental or investigational treatments, services, or items.

    • Experimental or investigational status includes, among other things, services or procedures considered investigational, cosmetic, or not medically necessary
    • Devices approved under the FDA Humanitarian Use Device exemption are not considered experimental or investigational
    • Drugs used in Phase 4 trials may be covered when they are part of the formulary
    • Members may refuse or participate in experimental or investigational items or services
    Denial Risk

    Insufficient Credible Evidence

    Even when an item or service is not initially deemed experimental or investigational under the policy criteria, CareSource may determine that it has that status when credible research does not soundly demonstrate a measurable and beneficial health outcome. Such a determination creates a denial risk.

    • Evidence may be insufficient when it is not conclusive concerning the effect on health outcomes
    • The evidence must demonstrate improved net health outcomes for the total population, with beneficial effects outweighing harmful effects
    • The service must be shown to be at least as beneficial as established alternatives
    • The evidence must demonstrate improved net health outcomes under usual conditions of medical practice outside clinical investigatory settings
    Institutional approvalSubject to review and approval by an institutional review board or similar body, with final approval not granted
    Clinical trial statusSubject of an ongoing FDA Phase 1, 2, or 3 clinical trial, including screening or diagnostic testing for possible trial inclusion
    Research or evaluation useProvided as part of a clinical research protocol or clinical trial, or otherwise to evaluate safety, toxicity, or efficacy
    Informed consentProvided under informed consent describing the item or service as experimental or investigational, or indicating that safety, toxicity, or efficacy is under evaluation
    Exceptions
    Humanitarian Use DeviceDevices FDA approved under the Humanitarian Use Device exemption are not considered experimental or investigational
    Phase 4 drugsDrugs used in Phase 4 trials may be covered if they are part of the formulary
    Phase 1–3 trialsDrugs, devices, or services associated with ongoing Phase 1, 2, or 3 clinical trials remain within the experimental or investigational review criteria